-
Lilly, Nektar to co-develop new immunotherapy
pharmatimes
July 26, 2017
Eli Lilly and Nektar Therapeutics have signed a pact to co-develop the latter’s experimental immunotherapy NKTR-358 for a range of autoimmune and other chronic inflammatory conditions under a deal valued at $400 million.
-
Lilly backs Nektar Therapeutics' novel immunological therapy
cphi-online
July 26, 2017
NKTR-358 has the potential to treat a number of autoimmune and other chronic inflammatory conditions.
-
Lilly reaches settlement agreement in US Cialis patent litigation
cphi-online
July 17, 2017
Cialis exclusivity is now expected to end at the earliest on 27 September 2018.
-
UK Supreme Court rules in Lilly's favour on Alimta vitamin regimen patents
cphi-online
July 13, 2017
Actavis's products directly infringe Lilly's vitamin regimen patents in the UK, France, Italy and Spain.
-
Eli Lilly to fund life science research at Purdue
biospectrumasia
July 10, 2017
Initial research areas include improving the delivery of injectable medicines to help reduce pain, decrease the number of injections and improve health.
-
Lilly and Incyte receive marketing approval for RA treatment Olumiant in Japan
pharmaceutical-technology
July 06, 2017
The Japanese Ministry of Health, Labour and Welfare (MHLW) has granted marketing approval for Olumiant (baricitinib) 2mg and 4mg tablets for the treatment of rheumatoid arthritis (RA).
-
Lilly's Olumiant gets the thumbs up in Japan for the treatment of rheumatoid arthritis
cphi-online
July 05, 2017
In clinical studies, baricitinib has demonstrated significant improvement in the signs and symptoms of RA compared to standard-of-care therapies.
-
NICE recommends Lilly’s Baricitinib (Olumiant) to treat rheumatoid arthritis
europeanpharmaceuticalreview
July 05, 2017
Baricitinib is the first JAK inhibitor to be recommended by NICE to treat rheumatoid arthritis in adults who have not responded to conventional therapy…
-
Lilly Diabetes Brings an Extra Splash of Summertime Fun and Inspiration to Diabetes Camps with Launc
lilly
June 28, 2017
This U.S. diabetes camp support program has provided speakers, scholarships, medicines and educational materials since 2001
-
Tackling dementia - Multipronged collaboration can accelerate progress
Lilly
June 28, 2017
This article comes from Laura Campo, Advisor - International Corporate Affairs, Alzheimer's disease at Eli Lilly and Company